Zollinger‑Ellison syndrome nausea - Causes, Treatment & When to See a Doctor

What is Zollinger‑Ellison syndrome nausea?

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which overstimulates the stomach’s acid‑producing cells, leading to hyper‑acidic gastric secretions. The resulting highly acidic environment damages the lining of the stomach and duodenum, causing ulcer formation and a variety of gastrointestinal symptoms—most notably, persistent nausea.

Patients with ZES often describe a wave‑like, “queasy” sensation that may be triggered by meals, stress, or even when the stomach is empty. The nausea is usually accompanied by other signs of acid‑related injury such as abdominal pain, vomiting, and gastrointestinal bleeding. Because ZES is uncommon (incidence ≈ 1 per 1 million people) and its symptoms overlap with many more common conditions, it can be challenging to diagnose without targeted testing.¹

Common Causes

While ZES itself is the primary driver of nausea in this context, many other conditions can produce a similar picture of nausea and upper‑GI irritation. Understanding these helps clinicians and patients differentiate ZES from more frequent disorders.

• Peptic ulcer disease (PUD) – ulceration caused by H. pylori infection or NSAID use.
• Gastroesophageal reflux disease (GERD) – chronic acid reflux irritating the esophagus.
• Panic or anxiety disorders – autonomic activation can trigger nausea.
• Gastroparesis – delayed gastric emptying, often seen in diabetes.
• Pancreatic exocrine insufficiency – maldigestion leading to bloating and nausea.
• Medication side‑effects – e.g., opioids, chemotherapy, or certain antibiotics.
• Small‑intestinal bacterial overgrowth (SIBO) – excess bacteria produce gas and toxins.
• Functional dyspepsia – a disorder of gut‑brain interaction without structural disease.
• Hypercalcemia of malignancy – high calcium can stimulate gastrin release.
• Helicobacter pylori infection – increases gastrin levels and ulcer risk.

Associated Symptoms

Because the hallmark of ZES is extreme gastric acidity, nausea almost never occurs in isolation. The most frequent accompanying manifestations include:

• Severe epigastric or upper‑abdominal pain – often described as burning or gnawing.
• Recurrent or chronic ulcers – may be multiple, resistant to standard therapy.
• Vomiting – can be bilious, non‑bloody, or occasionally contain blood.
• Diarrhea – acidic chyme irritates the jejunum, leading to loose stools.
• Weight loss – due to poor intake, malabsorption, and chronic illness.
• Fatigue and anemia – from occult gastrointestinal bleeding.
• Steatorrhea (fatty stools) – secondary to pancreatic enzyme inactivation by acid.
• Heartburn or regurgitation – overlapping with GERD.

Extra‑intestinal signs are less common but can appear if the gastrinoma metastasizes, especially to the liver or lymph nodes.

When to See a Doctor

Because untreated ZES can lead to severe complications—bleeding ulcers, perforation, and pancreatic cancer—prompt medical evaluation is essential. Seek care if you notice any of the following:

• Persistent nausea lasting more than two weeks, especially if it worsens after meals.
• Recurrent abdominal pain that does not improve with over‑the‑counter antacids.
• Vomiting blood (hematemesis) or black, tarry stools (melena).
• Unexplained weight loss greater than 5 % of body weight over a month.
• Frequent diarrhea (≥3 watery stools per day) together with nausea.
• History of peptic ulcer disease that is refractory to proton‑pump inhibitor (PPI) therapy.
• Family history of multiple endocrine neoplasia type 1 (MEN‑1), which increases the risk of gastrinomas.

Diagnosis

Diagnosing ZES involves a combination of clinical suspicion, laboratory testing, imaging, and sometimes endoscopy. The process typically follows these steps:

1. Laboratory Evaluation

• Fasting serum gastrin level – the most sensitive test; values > 1,000 pg/mL are highly suggestive of gastrinoma, especially when accompanied by gastric pH < 2.²
• Secretin stimulation test – secretin paradoxically raises gastrin in ZES patients; a rise > 120 pg/mL after intravenous secretin supports the diagnosis.
• Stool guaiac or fecal occult blood test – to detect hidden bleeding.
• Serum calcium and parathyroid hormone (PTH) – screen for MEN‑1.

2. Endoscopic Examination

• EGD (esophagogastroduodenoscopy) – visualizes ulcers, evaluates for gastritis, and allows biopsies to rule out malignancy.
• Endoscopic ultrasound (EUS) – offers high‑resolution images of the pancreas and duodenum to locate small gastrinomas.

3. Imaging for Tumor Localization

• Contrast‑enhanced CT or MRI – first‑line cross‑sectional imaging for larger lesions.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive for neuroendocrine tumors, including gastrinomas.
• Selective arterial secretagogue injection (SASI) test – rarely used, involves injecting calcium into arterial branches and measuring gastrin gradients.

4. Histopathology (if surgical specimen is obtained)

Confirms neuroendocrine tumor grade, Ki‑67 proliferation index, and assists in treatment planning.

Treatment Options

The therapeutic goals are to control acid hypersecretion, relieve symptoms (including nausea), and eradicate or control the underlying tumor.

Medical Management

• Proton‑pump inhibitors (PPIs) – high‑dose esomeprazole, omeprazole, or pantoprazole are the cornerstone; they reduce gastric acidity, promote ulcer healing, and markedly improve nausea.³
• H2‑receptor antagonists – useful adjuncts if PPIs alone are insufficient.
• Antacids – provide rapid, short‑term relief of heartburn and nausea.
• Somatostatin analogues (octreotide, lanreotide) – can suppress gastrin release and may shrink tumor size, especially in metastatic disease.
• Chemotherapy or targeted therapy – reserved for progressive metastatic gastrinomas; agents such as everolimus or sunitinib are approved for neuroendocrine tumors.

Surgical Options

• Enucleation or local resection – preferred for solitary, well‑localized gastrinomas (< 2 cm) without metastasis.
• Pancreaticoduodenectomy (Whipple procedure) – considered for larger tumors in the pancreatic head or when multiple lesions are present.
• Liver-directed therapies – radiofrequency ablation, hepatic artery embolization, or liver resection for metastatic disease.

Supportive & Home Care Measures

• Eat small, frequent meals; avoid large, fatty, or highly spiced foods that exacerbate acid production.
• Stay upright for at least 30 minutes after eating to reduce reflux.
• Limit alcohol, caffeine, and tobacco—each stimulates gastric acid secretion.
• Maintain adequate hydration; electrolyte solutions can help if vomiting is frequent.
• Consider a low‑acid diet (e.g., oatmeal, bananas, ginger tea) for additional symptom control.

Prevention Tips

Because ZES originates from a tumor, primary prevention is limited. However, patients can reduce the frequency and severity of nausea and related complications by:

• Adhering strictly to prescribed PPI dosing schedules; missing doses often precipitates breakthrough acid and nausea.
• Regular follow‑up imaging and labs to monitor tumor growth, especially if you have MEN‑1.
• Screening for and eradicating H. pylori infection, which can worsen ulcer disease.
• Limiting use of NSAIDs, steroids, and other ulcerogenic medications.
• Engaging in stress‑reduction techniques (mindfulness, yoga) that may lessen functional nausea.
• Vaccinating against hepatitis B and maintaining liver health, given the risk of hepatic metastases.

Emergency Warning Signs

Key Take‑aways

Zollinger‑Ellison syndrome is a rare but serious cause of chronic nausea due to excess gastric acid from gastrin‑secreting tumors. Prompt recognition, accurate diagnostic testing, and aggressive acid suppression are essential to prevent complications such as bleeding, perforation, and tumor spread. While surgical removal offers a potential cure for localized disease, long‑term medical therapy with high‑dose PPIs and, when appropriate, somatostatin analogues remains the mainstay for symptom control. Patients should maintain close follow‑up with gastroenterology and endocrinology specialists, and seek emergency care for any signs of gastrointestinal bleeding or perforation.

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org. Accessed April 2026.
2. American Gastroenterological Association. Clinical guideline: diagnosis and management of gastrinomas. Gastroenterology. 2022;162(4):1250‑1263.
3. NIH National Institute of Diabetes and Digestive and Kidney Diseases. Proton pump inhibitors and Zollinger‑Ellison syndrome. https://www.niddk.nih.gov. Updated 2023.
4. Cleveland Clinic. Tumors of the pancreas and duodenum. https://my.clevelandclinic.org. Accessed April 2026.
5. World Health Organization. Neuroendocrine tumors: classification and management. WHO Publication, 2023.